Evidence map›Paper›PMID 25606687›Full record

ArticleBiophysical journal2015

Effects of HCM cTnI mutation R145G on troponin structure and modulation by PKA phosphorylation elucidated by molecular dynamics simulations.

Steffen Lindert, Yuanhua Cheng, Peter Kekenes-Huskey, Michael Regnier, J Andrew McCammon

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Cardiomyocyte Dysfunction in Inherited Cardiomyopathies.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Troponin structure and function: a view of recent progress.Journal of muscle research and cell motility · 2020
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Steffen LindertDepartment of Pharmacology, University of California San Diego, La Jolla, California; NSF Center for Theoretical Biological Physics, La Jolla, California. Electronic address: slindert@ucsd.edu.
Yuanhua ChengDepartment of Bioengineering, University of Washington, Seattle, Washington.
Peter Kekenes-HuskeyDepartment of Pharmacology, University of California San Diego, La Jolla, California; Department of Chemistry, University of Kentucky, Lexington, Kentucky.
Michael RegnierDepartment of Bioengineering, University of Washington, Seattle, Washington.
J Andrew McCammonDepartment of Pharmacology, University of California San Diego, La Jolla, California; Howard Hughes Medical Institute, University of California San Diego, La Jolla, California; Department of Chemistry and Biochemistry, National Biomedical Computation Resource, University of California San Diego, La Jolla, California; NSF Center for Theoretical Biological Physics, La Jolla, California.
Center for Theoretical Biological Physics · USUniversity of Washington · USUniversity of Kentucky · US

Funding

THEORY OF BIOMOLECULAR DIFFUSIONR01GM031749 · NIGMS · UNIVERSITY OF HOUSTON · PI HUBER, GARY ALEXANDER, MCCAMMON, JAMES ANDREW · 1985 to 2022
$7.8M
Bioengineering Cardiovascular Training GrantT32EB001650 · NIBIB · UNIVERSITY OF WASHINGTON · PI REGNIER, MICHAEL · 2004 to 2019
$3.6M
EFFECT OF R1R2 OVER-EXPRESSION ON CARDIAC FUNCTIONR01HL111197 · NHLBI · UNIVERSITY OF WASHINGTON · PI REGNIER, MICHAEL · 2012 to 2015
$2.3M
Computationally designed phospholamban-SERCA for rectifying diabetic cardiomyopaF32HL114365 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KEKENES-HUSKEY, PETER MICHAEL · 2013 to 2013
$44k
NHLBI NIH HHS 1F32HL114365-01A1NHLBI NIH HHS F32 HL114365NHLBI NIH HHS R01 HL111197NIBIB NIH HHS T32 EB001650NIGMS NIH HHS R01 GM031749
6 · The paper itself

Abstract

Cardiac troponin (cTn) is a key molecule in the regulation of human cardiac muscle contraction. The N-terminal cardiac-specific peptide of the inhibitory subunit of troponin, cTnI (cTnI(1-39)), is a target for phosphorylation by protein kinase A (PKA) during β-adrenergic stimulation. We recently presented evidence indicating that this peptide interacts with the inhibitory peptide (cTnl(137-147)) when S23 and S24 are phosphorylated. The inhibitory peptide is also the target of the point mutation cTnI-R145G, which is associated with hypertrophic cardiomyopathy (HCM), a disease associated with sudden death in apparently healthy young adults. It has been shown that both phosphorylation and this mutation alter the cTnC-cTnI (C-I) interaction, which plays a crucial role in modulating contractile activation. However, little is known about the molecular-level events underlying this modulation. Here, we computationally investigated the effects of the cTnI-R145G mutation on the dynamics of cTn, cTnC Ca(2+) handling, and the C-I interaction. Comparisons were made with the cTnI-R145G/S23D/S24D phosphomimic mutation, which has been used both experimentally and computationally to study the cTnI N-terminal specific effects of PKA phosphorylation. Additional comparisons between the phosphomimic mutations and the real phosphorylations were made. For this purpose, we ran triplicate 150 ns molecular dynamics simulations of cTnI-R145G Ca(2+)-bound cTnC(1-161)-cTnI(1-172)-cTnT(236-285), cTnI-R145G/S23D/S24D Ca(2+)-bound cTnC(1-161)-cTnI(1-172)-cTnT(236-285), and cTnI-R145G/PS23/PS24 Ca(2+)-bound cTnC(1-161)-cTnI(1-172)-cTnT(236-285), respectively. We found that the cTnI-R145G mutation did not impact the overall dynamics of cTn, but stabilized crucial Ca(2+)-coordinating interactions. However, the phosphomimic mutations increased overall cTn fluctuations and destabilized Ca(2+) coordination. Interestingly, cTnI-R145G blunted the intrasubunit interactions between the cTnI N-terminal extension and the cTnI inhibitory peptide, which have been suggested to play a crucial role in modulating troponin function during β-adrenergic stimulation. These findings offer a molecular-level explanation for how the HCM mutation cTnI-R145G reduces the modulation of cTn by phosphorylation of S23/S24 during β-adrenergic stimulation.

Indexed as

Molecular Dynamics SimulationMutation, MissenseProtein Processing, Post-TranslationalAmino Acid SequenceCardiomegalyCyclic AMP-Dependent Protein KinasesHumansMolecular Sequence DataPhosphorylationTroponin ICyclic AMP-Dependent Protein KinasesTroponin I

Identifiers

PMID25606687
PMCPMC4302190
OpenAlexW2096163961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.